Meaghen E. Sharik

695 total citations
14 papers, 329 citations indexed

About

Meaghen E. Sharik is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Meaghen E. Sharik has authored 14 papers receiving a total of 329 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 10 papers in Hematology and 5 papers in Oncology. Recurrent topics in Meaghen E. Sharik's work include Multiple Myeloma Research and Treatments (10 papers), Protein Degradation and Inhibitors (6 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Meaghen E. Sharik is often cited by papers focused on Multiple Myeloma Research and Treatments (10 papers), Protein Degradation and Inhibitors (6 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Meaghen E. Sharik collaborates with scholars based in United States, Germany and Canada. Meaghen E. Sharik's co-authors include P. Leif Bergsagel, Marta Chesi, Victoria M. Garbitt, Shaji Kumar, Erin W. Meermeier, Enric Esplugues, Arianna Brevi, Giovanni Tonon, S. Vincent Rajkumar and Richard A. Flavell and has published in prestigious journals such as Nature Communications, Blood and Cancer Research.

In The Last Decade

Meaghen E. Sharik

14 papers receiving 328 citations

Peers

Countries citing papers authored by Meaghen E. Sharik

Since Specialization

Citations

This map shows the geographic impact of Meaghen E. Sharik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meaghen E. Sharik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meaghen E. Sharik more than expected).

Fields of papers citing papers by Meaghen E. Sharik

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Meaghen E. Sharik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meaghen E. Sharik. The network helps show where Meaghen E. Sharik may publish in the future.

Co-authorship network of co-authors of Meaghen E. Sharik

This figure shows the co-authorship network connecting the top 25 collaborators of Meaghen E. Sharik. A scholar is included among the top collaborators of Meaghen E. Sharik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Meaghen E. Sharik. Meaghen E. Sharik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	An immunostimulatory CELMoD combination overcomes resistance to T-cell engagers caused by a high multiple myeloma burden 2025 ·Blood ·Erin W. Meermeier, (unknown), Joshua Epstein, Meaghen E. Sharik, (unknown), (unknown), Chang‐Xin Shi, Yuan Xiao Zhu, P. Leif Bergsagel, Marta Chesi	2
2	Abundance of C1q Expressing Macrophages Promotes Resistance to Modern Therapy 2024 ·Blood ·Caleb K. Stein, Erin W. Meermeier, (unknown), Yuan Xiao Zhu, (unknown), (unknown), (unknown), Meaghen E. Sharik, Leif Bergsagel, (unknown)	1
3	The genomic landscape of VkMYC myeloma highlights shared pathways of transformation between mice and humans 2024 ·Nature Communications* ·Francesco Maura, David G. Coffey, Caleb K. Stein, Esteban Braggio, Bachisio Ziccheddu, Meaghen E. Sharik, (unknown), (unknown), (unknown), Yuan Xiao Zhu, Erin W. Meermeier, Gareth J. Morgan, Ola Landgren, P. Leif Bergsagel, Marta Chesi	4
4	Celmod-Dexamethasone Combination Overcomes Primary Resistance to T Cell Engagers Caused By High Tumor Burden in a Human CRBN+ Preclinical Model of Multiple Myeloma 2024 ·Blood ·Erin W. Meermeier, Meaghen E. Sharik, (unknown), Joshua Epstein, Yuan Xiao Zhu, Chang‐Xin Shi, (unknown), Leif Bergsagel, (unknown)	1
5	Transplantation of autologous bone marrow pre-loaded ex vivo with oncolytic myxoma virus is efficacious against drug-resistant VkMYC mouse myeloma 2022 ·Oncotarget* ·Nancy Villa, Masmudur M. Rahman, (unknown), Meaghen E. Sharik, Ana Lemos de Matos, Jacquelyn Kilbourne, (unknown), (unknown), (unknown), (unknown), Marta Chesi, P. Leif Bergsagel, (unknown)	4
6	Abstract 5588: PD-1 blockade synergizes with IMiDs to enhance bispecific T cell engager immune responses to VkMYChCRBN multiple myeloma by preventing T cell exhaustion 2022 ·Cancer Research* ·Erin W. Meermeier, Seth J. Welsh, Meaghen E. Sharik, (unknown), (unknown), Bryant Chau, (unknown), Matthew L. Wheeler, Natalie Bezman, Pavel Strop, P. Leif Bergsagel, (unknown)	1
7	VκMYC Mouse Model Recapitulates Key Genomic Defining Events in Multiple Myeloma 2022 ·Blood* ·Francesco Maura, David G. Coffey, Esteban Braggio, Caleb K. Stein, Meaghen E. Sharik, (unknown), Bachisio Ziccheddu, Gareth J. Morgan, Ola Landgren, P. Leif Bergsagel, (unknown)	1
8	Tumor Burden Limits Bispecific Antibody Efficacy through T-cell Exhaustion Averted by Concurrent Cytotoxic Therapy 2021 ·Blood Cancer Discovery ·Erin W. Meermeier, Seth J. Welsh, Meaghen E. Sharik, (unknown), Victoria M. Garbitt, Daniel L. Riggs, Chang‐Xin Shi, Caleb K. Stein, (unknown), Bryant Chau, Matthew L. Wheeler, Natalie Bezman, (unknown), Pavel Strop, P. Leif Bergsagel, Marta Chesi	67
9	Disrupting Ectopic Super-Enhancers to Treat Multiple Myeloma 2021 ·Blood ·Seth J. Welsh, Daniel L. Riggs, Erin W. Meermeier, (unknown), Victoria M. Garbitt, Meaghen E. Sharik, (unknown), (unknown), (unknown), (unknown), Caleb K. Stein, Paola Neri, Nizar J. Bahlis, Benjamin G. Barwick, (unknown), W. Michael Kuehl, Marta Chesi, P. Leif Bergsagel	1
10	Monosomic Loss of MIR15A/MIR16-1 Is a Driver of Multiple Myeloma Proliferation and Disease Progression 2020 ·Blood Cancer Discovery ·Marta Chesi, Caleb K. Stein, Victoria M. Garbitt, Meaghen E. Sharik, Yan W. Asmann, (unknown), Daniel L. Riggs, Seth J. Welsh, Erin W. Meermeier, Shaji Kumar, Esteban Braggio, P. Leif Bergsagel	20
11	Identification of PIKfyve kinase as a target in multiple myeloma 2019 ·Haematologica ·Cecília Bonolo de Campos, Yuan Xiao Zhu, Nikolai Sepetov, Sergei Romanov, Laura A. Bruins, Chang-Xin Shi, Caleb K. Stein, Joachim L. Petit, (unknown), Meaghen E. Sharik, Erin W. Meermeier, Gregory Ahmann, (unknown), (unknown), P. Leif Bergsagel, Marta Chesi, Nathalie Meurice, Esteban Braggio, A. Keith Stewart	24
12	Inhibitors of the protein disulfide isomerase family for the treatment of multiple myeloma 2018 ·Leukemia ·Reeder M. Robinson, Leticia Reyes, (unknown), (unknown), Allen B. Reitz, Yefim Manevich, Jesse J. McClure, Matthew M. Champion, C. James Chou, Meaghen E. Sharik, Marta Chesi, P. Leif Bergsagel, Nathan G. Dolloff	42
13	Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression 2018 ·Nature Communications ·Arianna Calcinotto, Arianna Brevi, Marta Chesi, Roberto Ferrarese, Laura García Pérez, Matteo Grioni, Shaji Kumar, Victoria M. Garbitt, Meaghen E. Sharik, Kimberly J. Henderson, Giovanni Tonon, Michio Tomura, Yoshihiro Miwa, Enric Esplugues, Richard A. Flavell, Samuel Huber, Filippo Canducci, S. Vincent Rajkumar, P. Leif Bergsagel, Matteo Bellone	158
14	A Single-Cell Transcriptional Analysis of Tumour Cells and the Immune Microenvironment during Disease Evolution in a Transgenic Mouse Model of Myeloma 2018 ·Blood ·Danielle Croucher, Marta Chesi, Zhihua Li, Victoria M. Garbitt, Meaghen E. Sharik, Daniel D. Waller, Michaël Sébag, P. Leif Bergsagel, Trevor J. Pugh, Suzanne Trudel	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact